Thursday, October 26, 2023
Inspira™ Technologies, a pioneering company dedicated to advancing acute respiratory care through innovative non-lung-dependent breathing solutions, proudly announced the acquisition of a new patent from the U.S. Patent and Trademark Office. This recent patent pertains to an inventive automated self-priming module designed for their respiratory medical device, the INSPIRATM ART500.
This groundbreaking self-automated priming module is a significant milestone for the INSPIRA ART500, as it prioritizes patient safety by ensuring a clot-free connection to the patient's vascular system. This innovation holds the potential to reduce the risk of clot formation and subsequent impediments to blood flow. The patent includes nine distinct claims, each demonstrating its uniqueness, inventive value, and practical applicability.
Notably, Inspira™ Technologies has taken steps to protect their innovative technology on a global scale, initiating patent applications not only in the United States but also in Europe and several other regions. In a healthcare landscape serving roughly 20 million patients annually, many of whom require mechanical ventilation and are exposed to associated risks and medical complications, the INSPIRA ART500 offers a promising solution. It aims to lessen the dependence on mechanical ventilation systems, which have been linked to a substantial 50% mortality rate, an elevated risk of coma, and the potential for bacterial infections and injuries associated with mechanical ventilation.
Source: prnewswire.com
